Use of amphotericin B during pregnancy: case report and review.
Unlike the situation with many antimicrobial agents, there is limited experience with the use of amphotericin B during pregnancy. Although reports of fungal infections during pregnancy have been published, few describe fungemia with either Candida or Torulopsis species. We present a case of fungemia due to Torulopsis glabrata that occurred during pregnancy and that was treated with amphotericin B. Drug concentrations were measured in placental tissue, cord serum, and infant serum at delivery. Although the last dose of amphotericin B was administered 4 weeks before delivery, the concentrations in all three specimens were still within the MIC ranges for most strains of Candida albicans and T. glabrata as measured by broth dilution. We speculate that persistent tissue concentrations of amphotericin B most likely contributed to the sustained hypokalemia in the mother and the increased creatinine level in the infant. In the latter case, placental tissue may have served as the reservoir from which amphotericin B was slowly released into fetal circulation.
Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
J L
JL
Dean
J E
JE
Wolf
A C
AC
Ranzini
M A
MA
Laughlin
D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002177:Candidiasis / Q000150:complications* / Q000188:drug therapy* / Q000378:metabolism; D003404:Creatinine / Q000097:blood; D005260:Female; D016469:Fungemia / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007008:Hypokalemia / Q000209:etiology; D007231:Infant, Newborn; D010920:Placenta / Q000378:metabolism; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000378:metabolism
D000666:Amphotericin B; D003404:Creatinine